PMID- 25336628
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 125
IP  - 1
DP  - 2015 Jan 1
TI  - Lack of durable disease control with chemotherapy for mycosis fungoides and 
      Sezary syndrome: a comparative study of systemic therapy.
PG  - 71-81
LID - 10.1182/blood-2014-07-588236 [doi]
AB  - Numerous systemic treatment options exist for patients with mycosis fungoides 
      (MF) and Sezary syndrome (SS), but no large comparative studies are published. To 
      study the efficacy of treatments, a retrospective analysis of our cutaneous 
      lymphoma database was undertaken, with 198 MF/SS patients undergoing systemic 
      therapies. The primary end point was time to next treatment (TTNT). Patients with 
      advanced-stage disease made up 53%. The median follow-up time from diagnosis for 
      all alive patients was 4.9 years (range 0.3-39.6), with a median survival of 11.4 
      years. Patients received a median of 3 lines of therapy (range 1-13), resulting 
      in 709 treatment episodes. Twenty-eight treatment modalities were analyzed. The 
      median TTNT for single- or multiagent chemotherapy was only 3.9 months (95% 
      confidence interval [CI] 3.2-5.1), with few durable remissions. alpha-interferon gave 
      a median TTNT of 8.7 months (95% CI 6.0-18.0), and histone deacetylase inhibitors 
      (HDACi) gave a median TTNT of 4.5 months (95% CI 4.0-6.1). When compared directly 
      with chemotherapy, interferon and HDACi both had greater TTNT (P < .00001 and P = 
      .01, respectively). This study confirms that all chemotherapy regimens assessed 
      have very modest efficacy; we recommend their use be restricted until other 
      options are exhausted.
CI  - (c) 2015 by The American Society of Hematology.
FAU - Hughes, Charlotte F M
AU  - Hughes CF
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of 
      Melbourne, Parkville, Australia;
FAU - Khot, Amit
AU  - Khot A
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - McCormack, Christopher
AU  - McCormack C
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      Australia; Department of Dermatology, St. Vincent's Hospital Department of 
      Medicine, Melbourne, Australia;
FAU - Lade, Stephen
AU  - Lade S
AD  - Division of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia; and.
FAU - Westerman, David A
AU  - Westerman DA
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of 
      Melbourne, Parkville, Australia; Division of Pathology, Peter MacCallum Cancer 
      Centre, Melbourne, Australia; and.
FAU - Twigger, Robert
AU  - Twigger R
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - Buelens, Odette
AU  - Buelens O
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - Newland, Kate
AU  - Newland K
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - Tam, Constantine
AU  - Tam C
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - Dickinson, Michael
AU  - Dickinson M
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - Ryan, Gail
AU  - Ryan G
AD  - Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, 
      Australia.
FAU - Ritchie, David
AU  - Ritchie D
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of 
      Melbourne, Parkville, Australia;
FAU - Wood, Colin
AU  - Wood C
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia;
FAU - Prince, H Miles
AU  - Prince HM
AD  - Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, 
      Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of 
      Melbourne, Parkville, Australia;
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141021
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Interferon-alpha)
SB  - IM
CIN - Blood. 2015 Jan 1;125(1):4-5. PMID: 25554742
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biopsy
MH  - Combined Modality Therapy
MH  - Drug Therapy/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - Histone Deacetylase Inhibitors/therapeutic use
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mycosis Fungoides/*drug therapy
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Sezary Syndrome/*drug therapy
MH  - Skin Neoplasms/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2014/10/23 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/10/23 06:00
PHST- 2014/10/23 06:00 [entrez]
PHST- 2014/10/23 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - S0006-4971(20)39529-X [pii]
AID - 10.1182/blood-2014-07-588236 [doi]
PST - ppublish
SO  - Blood. 2015 Jan 1;125(1):71-81. doi: 10.1182/blood-2014-07-588236. Epub 2014 Oct 
      21.